AzTrials
AzTrials

PaediatricNCT07841340

The Efficacy and Safety of Adjunctive Alpha-blocker Therapy Before Flexible Ureteroscopy in the Management of Upper Ureteric Stones in Pediatrics Group

A study testing Tamsulosin in people with Paediatric and Flexible Ureteroscopy, run by Ain Shams University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A unique aspect of pediatric URS is the smaller ureteral diameter, which often results in failure to access the ureter during an initial URS attempt. Ureteral orifice navigation is often limited at the level of the ureteral orifice or intramural ureter. Read more about this study

Who is it for?
Ages 5 to 18 years
Conditions the study is for
Paediatric, Flexible Ureteroscopy
What is being tested?
Tamsulosin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteEgypt
Study dates
4 Sep 2022to 1 Sep 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 5 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Age between 5:18 years
  • Children with upper ureteric stones

Who cannot join

  • Children with active urosepsis.
  • Children with ureteral stricture
  • Children with past history of ureteric endoscopy or stent application.
  • Children with bilateral ureteral stones.
  • Children with congenital anomalies e.g. solitary kidney, duplex system, ureterocele.
  • Those with hypersensitivity to α-blockers.
  • Known hypotensive or bradycardic patients.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Ainshams university

    Cairo, Cairo Governorate

Other trials in Egypt

About this study

A unique aspect of pediatric URS is the smaller ureteral diameter, which often results in failure to access the ureter during an initial URS attempt.

Ureteral orifice navigation is often limited at the level of the ureteral orifice or intramural ureter. α1 adrenergic receptors are densely located at this level, and α-antagonists can reduce the tension of the intramural segment The purpose of this study was to evaluate if preoperative treatment with tamsulosin is associated with an increased rate of successful first-time ureteral orifice navigation in a school-age pediatric population, defined as patients 5-18 years old.

Read the detailed description

The incidence of pediatric urolithiasis has risen dramatically over the past few decades, with a reported rate of 4% per year .There is controversy regarding the practice of routine prestenting and balloon dilation to gain ureteral access in children. The AUA guidelines recommend against the routine use of prestenting. Balloon dilation of the ureteral orifice carries the risk of ureteral perforation and ureteral stricture, due to tissue ischemia .There are three subtypes of alpha- 1 adrenoceptors (ARs) in the ureteric wall: alpha-1A, alpha-1B and alpha-1D. In the proximal ureter, the distribution of ARs was alpha-1D ≥alpha-1B >alpha-1A. In the distal and middle ureters, the distribution of ARs was alpha-1D > alpha-1A > alpha-1B . Tamsulosin acts on α1A and α1D receptors causing the relaxation of the ureteric wall, which consequently increases the urine bolus and intra-ureteral pressure above the stone and lowers intra-ureteral pressure below the stone by decreasing peristalsis in association with the decrease in basal and micturition pressure, even at the bladder neck; thus, it increases the chance of stone expulsion .The management of ureteric stones consists of observation, medical expulsive therapy (MET), shockwave lithotripsy (SWL), ureteroscopy, percutaneous nephrolithotomy or open and laparoscopic stone surgery, depending on the clinical situation .The presumed mechanism of action of alphablockers is the inhibition of smooth muscle contraction in the ureter, causing relaxation of the ureter smooth muscle and reducing the strength and frequency of peristalsis .Flexible ureteroscopy (FURS) has been applied in recent years to the treatment of urinary stones. FURS presents overt advantages over other techniques, including improved resolution and increased optical field, high stone-free rate, reduced risk of bleeding, limited surgical injury, good repeatability, and speedy recovery; in addition, further miniaturization is possible. In children and infants, who have a relatively high stone recurrence rate, FURS could be performed repeatedly. FURS and holmium laser lithotripsy in treating infants and children has been previously assessed in the literature; however, most reports were limited in sample size.

Aim of the study:To evaluate efficacy adjunctive alpha-blocker therapy before Flexible ureteroscopy in the management of Upper ureteric stones in children as regard facilitating ureteric orifice navigation, Ureteral Dilatation, intraoperative and postoperative Complication, patient satisfaction and stone free rate.

PATIENTS AND METHODS This was a prospective randomized control study that was conducted at tertiary care hospital between September 2022 till September 2024. The study was approved by the Research Ethics Committee (REC) of Ain Shams University Faculty of Medicine. A detailed written informed consent was secured from patients' parents included in the study before enrollment after explaining the benefits and risks of the medication and procedure.

Eligibility criteria We included all children aged between 5 and 18 years with upper ureteric stones. Patients excluded from the analysis were children with active urosepsis, ureteral stricture, bilateral ureteral stones, children with already stented ureter, Children with congenital anomalies e.g. solitary kidney, duplex system, ureterocele, Those with hypersensitivity to α-blockers and Known hypotensive or bradycardic patients.

Participants and group allocation A total of 80 patients were included and randomly allocated into two groups depending on simple one to one randomization utilizing a sealed envelope prepared by an independent third party to ensure unbiased distribution. Outcome assessors, and statisticians were blinded to the treatment to minimize bias.. Group A: 40 Children received Tamsulosin 0.4 mg capsule for 5 days prior to Flexible uretroscopy. Group B: 40 Children didn't receive Tamsulosin 0.4 mg capsule prior to Flexible uretroscopy.

Pre-treatment assessment and baseline investigations All patients underwent a thorough clinical history and physical examination. Detailed medical history and surgical history including any surgery of the urinary tract, DJ application and ESWL. Laboratory work up including complete blood count (CBC), kidney functions test, liver functions test, hepatitis markers, coagulation profile, completer urine analysis and urine culture with sensitivity. All patients were subjected to imaging studies including pelvi-abdominal ultrasound, plain X-ray of urinary tract and CTUT All patients performed KUB in the morning day of the operation.

Alpha Blocker (Tamsulosin) 0.4 mg/dl was given once daily before sleep for 5 days to Group A only. Patients received preoperative prophylactic antibiotic. All cases had been performed by the same standard approach for Flexible Uretroscopy

Flexible uretroscopy:

The procedures were performed under general anesthesia in frog leg or lithotomy position in all patients. we start with cystoscopy followed by guide-wire insertion up to the renal pelvis and retrograde pyelography. Ureteral dilation was performed by teflon dilators up to 8 fr Then, we attempt to advocate the 7.5 fr flexible ureteroscope over the guide wire under direct vision up to the stone level. In all cases, Stone disintegration was done using Holmium Laser System and 200-micron laser fiber in dusting mode. A double-J stent was placed at the end of the procedure. Urethral catheter was left at end of procedure. DJ stents was removed 2 - 4 weeks after the operation. If navigation of the ureteral orifice is unsuccessful, then a ureteral JJ stent is placed for 10-14 days before attempting a second URS.

Postoperative:

Postoperatively, all patient had CBC done a few hours after the procedure, monitored for vital signs and urine color. All patients were assessed for residual stone presence 3 weeks after procedure by CTUT. The intraoperative and postoperative complications (e.g. fever, hematuria…), stone-free rate, and hospital stay were were reported according to the modified Clavien grading system. The primary endpoint was defined as being able to engage the flexible ureteroscope in the ureteral orifice to be able to perform the intended procedure. The second endpoint are safety of tamsulosin, intraoperative and postoperative Complication.

Statistical Analysis Data were collected, revised, coded and entered to the Statistical Package for Social Science (IBM SPSS) version 20. The qualitative data were presented as number and percentages while quantitative data were presented as mean, standard deviations and ranges when their distribution found parametric.

The comparison between two groups with qualitative data were done by using Chi-square test and/or Fisher exact test was used instead of Chi-square test when the expected count in any cell was found less than 5. The comparison between two independent groups with quantitative data and parametric distribution was done by using Independent t-test.

The confidence interval was set to 95% and the margin of error accepted was set to 5%. So, the p-value was considered significant as the following: P> 0.05 = non significant (NS), P < 0.05 = significant (S) and P < 0.001 = highly significant (HS).

Being tested
Tamsulosin
Keywords
paediatric, alpha blocker, flexible ureteroscopy, tamsulosin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TamsulosinDrug

    Children will receive Tamsulosin 0.4 mg ( alpha blocker) capsule for 5 days prior to Flexible uretroscopy

Study groups in NCT07841340
Study groupRoleWhat they receive
interventionalExperimentalChildren with ureteric stones with age between 5:18 years will receive Tamsulosin 0.4 mg capsule for 5 days prior to Flexible uretroscopy
Receives: Drug: Tamsulosin
controlNo interventionChildren with ureteric stones with age between 5:18 years will not receive Tamsulosin 0.4 mg capsule prior to Flexible uretroscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants with Successful Flexible Ureteroscope Negotiation Through the Ureteral Orifice in tamsulosin group versus non tamsulosin group

    Successful negotiation is defined as advancement of the flexible ureteroscope through the ureteral orifice and into the ureter sufficiently to allow performance of the intended ureteroscopic procedure. The outcome will be recorded as the number and percentage of participants with successful negotiation in each treatment group

    Measured: Intraoperative, during flexible ureteroscopy

Secondary outcomes (2)
  1. Number of Participants with Intraoperative or Postoperative Complications Following Flexible Ureteroscopy

    Intraoperative and postoperative complications will be recorded for each participant. Complications will include ureteral injury, bleeding/hematuria, postoperative fever, urinary tract infection, ureteral perforation, postoperative pain requiring additional treatment, and other clinically relevant complications. Complications will be classified according to the modified Clavien-Dindo classification system. The outcome will be reported as the number and percentage of participants experiencing at least one complication in each treatment group.

    Measured: From the beginning of flexible ureteroscopy until 1 month postoperatively

  2. Number of Participants with Tamsulosin-Related Adverse Events Following Preoperative Tamsulosin Administration.

    Adverse events potentially related to tamsulosin will be assessed during the preoperative treatment period and perioperative period. Events assessed will include dizziness, headache, hypotension, orthostatic hypotension, syncope, gastrointestinal symptoms, and other clinically relevant adverse events. The outcome will be reported as the number and percentage of participants experiencing at least one treatment-related adverse event in each treatment group

    Measured: From initiation of tamsulosin until the day of surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Sep 2026
  2. Study start4 Sep 2022
  3. Primary completion4 Apr 2023
  4. Study completion1 Sep 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Model description
Children with ureteric stones ranging from 5-10 mm Age between 5:18 years
Masking
None (open label)
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07841340
Sponsor's protocol ID
FMASU MS569/2022
Status last verified
Sep 2026
First submitted
9 Sep 2026
Last updated
25 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Tamsulosin in people with Paediatric and Flexible Ureteroscopy, run by Ain Shams University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants with Successful Flexible Ureteroscope Negotiation Through the Ureteral Orifice in tamsulosin group versus non tamsulosin group (time frame: Intraoperative, during flexible ureteroscopy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in